Atea outlines runway into mid-2028 with $200M Hercules facility as it targets mid-2027 HCV NDA (NASDAQ:AVIR)
· seekingalpha.com
Atea Pharmaceuticals Q3 2026 earnings call: Phase III HCV progress, 2027 catalysts, and launch funding updates.
Earnings Call Insights Atea outlines runway into mid-2028 with $200M Hercules facility as it targets mid-2027 HCV NDA Nov 10, 2026, 2:01 AM ET Atea Pharmaceutic...